JP2011168588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011168588A5 JP2011168588A5 JP2011026980A JP2011026980A JP2011168588A5 JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5 JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- compound
- apoptosis inducer
- test compound
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000006907 apoptotic process Effects 0.000 claims 9
- 239000000411 inducer Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 108700008625 Reporter Genes Proteins 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011026980A JP5213972B2 (ja) | 2004-04-09 | 2011-02-10 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004115404 | 2004-04-09 | ||
| JP2004115404 | 2004-04-09 | ||
| JP2011026980A JP5213972B2 (ja) | 2004-04-09 | 2011-02-10 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006512126A Division JP4761389B2 (ja) | 2004-04-09 | 2005-04-08 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012046652A Division JP5390653B2 (ja) | 2004-04-09 | 2012-03-02 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011168588A JP2011168588A (ja) | 2011-09-01 |
| JP2011168588A5 true JP2011168588A5 (enExample) | 2012-04-19 |
| JP5213972B2 JP5213972B2 (ja) | 2013-06-19 |
Family
ID=35124844
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006512126A Expired - Fee Related JP4761389B2 (ja) | 2004-04-09 | 2005-04-08 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
| JP2011026980A Expired - Fee Related JP5213972B2 (ja) | 2004-04-09 | 2011-02-10 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
| JP2012046652A Expired - Fee Related JP5390653B2 (ja) | 2004-04-09 | 2012-03-02 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006512126A Expired - Fee Related JP4761389B2 (ja) | 2004-04-09 | 2005-04-08 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012046652A Expired - Fee Related JP5390653B2 (ja) | 2004-04-09 | 2012-03-02 | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8193332B2 (enExample) |
| EP (4) | EP2495324B1 (enExample) |
| JP (3) | JP4761389B2 (enExample) |
| KR (1) | KR101234281B1 (enExample) |
| WO (1) | WO2005097189A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4299299B2 (ja) | 2003-05-19 | 2009-07-22 | 株式会社ジーンケア研究所 | 癌細胞に対するアポトーシス誘導剤 |
| US8193332B2 (en) | 2004-04-09 | 2012-06-05 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| WO2006054625A1 (ja) | 2004-11-19 | 2006-05-26 | Genecare Research Institute Co., Ltd. | 癌細胞特異的細胞増殖抑制剤 |
| US20090208938A1 (en) * | 2005-02-10 | 2009-08-20 | Centre National De La Recherche Scientifique | Use of the MCM8 Gene for the Preparation of a Pharmaceutical Composition |
| JP5150855B2 (ja) * | 2005-07-29 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 |
| GB0606096D0 (en) * | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| JPWO2008047574A1 (ja) * | 2006-09-28 | 2010-02-25 | 株式会社ジーンケア研究所 | 抗癌剤増感剤 |
| JP4940412B2 (ja) * | 2006-10-16 | 2012-05-30 | 財団法人ヒューマンサイエンス振興財団 | 抗癌性物質のスクリーニング方法 |
| WO2008048119A2 (en) * | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| EP2350278A2 (en) * | 2008-09-23 | 2011-08-03 | Silence Therapeutics AG | Means for inhibiting the expression of orc-1 |
| WO2010045526A1 (en) * | 2008-10-17 | 2010-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Geminin inhibitors as tumor treatment |
| US20110237649A1 (en) * | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
| US20110319317A1 (en) * | 2009-03-04 | 2011-12-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
| US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
| US20110097329A1 (en) | 2009-06-26 | 2011-04-28 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| EP2985348B1 (en) * | 2009-07-24 | 2020-12-30 | CuRNA, Inc. | Treatment of sirtuin 6 (sirt6) related diseases by inhibition of natural antisense transcript to sirt6 |
| AU2011216404B2 (en) | 2010-02-17 | 2016-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20130071395A1 (en) * | 2010-05-28 | 2013-03-21 | Case Western Reserve University | Compositions and methods for treating pathologies |
| WO2012090479A1 (en) * | 2010-12-28 | 2012-07-05 | Oncotherapy Science, Inc. | Mcm7 as a target gene for cancer therapy and diagnosis |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9512486B2 (en) * | 2012-08-06 | 2016-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | Materials, methods, and systems for treating cancer |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| KR101623814B1 (ko) | 2014-02-21 | 2016-05-24 | 두산중공업 주식회사 | 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법 |
| JP2015167527A (ja) * | 2014-03-07 | 2015-09-28 | 学校法人東京理科大学 | 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体 |
| WO2016102517A1 (en) * | 2014-12-23 | 2016-06-30 | Centre National De La Recherche Scientifique | Use of rad18 inhibitors in the treatment of tumors |
| CN104673801B (zh) * | 2015-02-12 | 2018-09-11 | 中山大学附属第三医院 | 一种肝癌基因ndc80及其应用 |
| ES2806498T3 (es) | 2015-06-08 | 2021-02-17 | Arquer Diagnostics Ltd | Métodos para el análisis de una muestra de orina |
| EP4060344A1 (en) | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Methods and kits |
| EP3512535A4 (en) * | 2016-09-13 | 2020-05-06 | The Jackson Laboratory | TARGETED IMPROVED DNA DEMETHYLATION |
| KR102472521B1 (ko) * | 2016-10-26 | 2022-12-01 | 덴카 주식회사 | 변이형 인간 DNA 폴리메라아제 ε |
| US20200121703A1 (en) * | 2017-06-26 | 2020-04-23 | The Cleveland Clinic Foundation | Cancer treatment |
| WO2020055187A1 (ko) * | 2018-09-12 | 2020-03-19 | 기초과학연구원 | 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법 |
| JP2022020872A (ja) * | 2020-06-01 | 2022-02-02 | 均 石井 | 抗がん剤。 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0923738A1 (en) * | 1996-06-11 | 1999-06-23 | Advanced Research & Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
| GB0004193D0 (en) * | 2000-02-22 | 2000-04-12 | Isis Innovation | A genetic determinant for malignant melanoma |
| WO2002009573A2 (en) * | 2000-07-31 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of endometrial cancer |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
| US7241743B2 (en) | 2001-06-15 | 2007-07-10 | The Trustees Of Columbia University In The City Of New York | Sir2α-based therapeutic and prophylactic methods |
| WO2003046207A2 (en) * | 2001-11-27 | 2003-06-05 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1519736A2 (en) * | 2002-06-12 | 2005-04-06 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
| US8252520B2 (en) * | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| EP1620573A4 (en) * | 2003-04-15 | 2006-12-20 | Avalon Pharmaceuticals | DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| JP4299299B2 (ja) | 2003-05-19 | 2009-07-22 | 株式会社ジーンケア研究所 | 癌細胞に対するアポトーシス誘導剤 |
| US8193332B2 (en) | 2004-04-09 | 2012-06-05 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| WO2006054625A1 (ja) | 2004-11-19 | 2006-05-26 | Genecare Research Institute Co., Ltd. | 癌細胞特異的細胞増殖抑制剤 |
-
2005
- 2005-04-08 US US11/547,770 patent/US8193332B2/en not_active Expired - Fee Related
- 2005-04-08 JP JP2006512126A patent/JP4761389B2/ja not_active Expired - Fee Related
- 2005-04-08 WO PCT/JP2005/006914 patent/WO2005097189A1/ja not_active Ceased
- 2005-04-08 EP EP12004228.8A patent/EP2495324B1/en not_active Expired - Lifetime
- 2005-04-08 KR KR1020067023433A patent/KR101234281B1/ko not_active Expired - Fee Related
- 2005-04-08 EP EP12003008.5A patent/EP2481802B1/en not_active Expired - Lifetime
- 2005-04-08 EP EP12005593.4A patent/EP2520652B1/en not_active Expired - Lifetime
- 2005-04-08 EP EP05728503A patent/EP1757306A4/en not_active Withdrawn
-
2011
- 2011-02-10 JP JP2011026980A patent/JP5213972B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-02 JP JP2012046652A patent/JP5390653B2/ja not_active Expired - Fee Related
- 2012-05-16 US US13/473,328 patent/US8470798B2/en not_active Expired - Fee Related
-
2013
- 2013-05-22 US US13/900,380 patent/US8703930B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011168588A5 (enExample) | ||
| Zhang et al. | Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1 | |
| Liu et al. | MicroRNA-34a promotes renal fibrosis by downregulation of klotho in tubular epithelial cells | |
| JP2011037847A5 (enExample) | ||
| Greussing et al. | Identification of microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts | |
| Schmitt et al. | Long noncoding RNAs in cancer pathways | |
| Neudecker et al. | Emerging roles for microRNAs in perioperative medicine | |
| Crea et al. | EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis | |
| Yu et al. | Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells | |
| Alegre et al. | Circulating biomarkers in malignant melanoma | |
| Li et al. | MiR‐125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway | |
| Wang et al. | microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis | |
| Skommer et al. | Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death | |
| Nidadavolu et al. | Identification of microRNAs dysregulated in cellular senescence driven by endogenous genotoxic stress | |
| Yang et al. | miR‑155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy | |
| Wang et al. | miR-197: A novel biomarker for cancers | |
| Wang et al. | Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9 | |
| JP2011162558A5 (enExample) | ||
| HK1200837A1 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| WO2014022826A3 (en) | Biomarker associated with risk of melanoma reoccurrence | |
| JP2012050449A5 (enExample) | ||
| Lambrecht et al. | The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis | |
| Zheng et al. | MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1 Retraction in/10.3892/ol. 2021.12905 | |
| NO20092965L (no) | Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner | |
| WO2014162008A3 (en) | Biomarker signatures for predicting drug response in hodkin's lymphoma |